Farrow Financial Inc. Lineage Cell Therapeutics, Inc. Transaction History
Farrow Financial Inc.
- $147 Billion
- Q2 2024
A detailed history of Farrow Financial Inc. transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Farrow Financial Inc. holds 11,500 shares of LCTX stock, worth $10,465. This represents 0.01% of its overall portfolio holdings.
Number of Shares
11,500
Previous 11,500
-0.0%
Holding current value
$10,465
Previous $17 Million
32.61%
% of portfolio
0.01%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding LCTX
# of Institutions
121Shares Held
94.3MCall Options Held
31.3KPut Options Held
400-
Broadwood Capital Inc New York, NY41.7MShares$37.9 Million3.19% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$8.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.47MShares$7.71 Million0.0% of portfolio
-
Defender Capital, Llc.4.97MShares$4.53 Million1.77% of portfolio
-
Logos Global Management LP San Francisco, CA4.7MShares$4.28 Million0.44% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $154M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...